Best Leukemia, Lymphoma and Blood Cancer Treatment Doctors and Hospitals in India: A Selection Guide for Bangladeshi Patients

Author:- Dr. Dheeraj Bojwani Date Created:- 03-08-2026

How to evaluate credentials, experience and hospital infrastructure so you choose with confidence — not guesswork — before you travel. Every year, thousands of Bangladeshi patients travel to India for leukemia, lymphoma and other blood cancer treatment, drawn by a combination of experienced haematology-oncology teams, internationally accredited hospitals and costs that run a fraction of what the same treatment costs in the UK or US. But "going to India" is not, by itself, a strategy. Blood cancers are genuinely diverse at a molecular level, and accurate subtyping through bone marrow biopsy, flow cytometry and genetic testing determines which treatment protocol gives you the best chance, far more than for many solid tumours. The outcome you get depends entirely on which specific team and which specific hospital you choose. This guide sets out exactly how to evaluate both, so your decision is based on real, checkable criteria rather than a brochure or a stranger's recommendation.

Healing Journeys of Bangladeshi Patients

Bangladeshi Patients Share Their Experience

Key Takeaways

• Leukemia, lymphoma and other blood cancers are highly diverse diseases, and the guide emphasises that accurate diagnosis and molecular subtyping are central to choosing an appropriate treatment protocol. Bone marrow biopsy, flow cytometry and genetic or molecular testing may provide information that changes treatment decisions, making diagnostic accuracy particularly important before treatment is finalised.
• The individual haematology-oncology specialist or team is presented as the most important selection decision rather than the hospital's marketing or general reputation. Bangladeshi patients should verify the doctor's registration through the National Medical Commission or relevant State Medical Council and look for postgraduate qualifications with specific fellowship training in haematology or medical oncology focused on blood cancers.
• Patients should ask about subtype-specific experience instead of relying on a general statement such as "20 years of experience." The guide recommends asking how many patients with the patient's exact diagnosis and molecular subtype the team personally manages each year, because treatment protocols and expected outcomes can differ substantially between blood cancer subtypes.
• Complete diagnostic subtyping should be established before the treatment protocol is finalised. Patients should specifically ask what bone marrow, flow cytometry and genetic or molecular investigations will be performed and why. Starting a generic treatment protocol before adequate diagnostic information is available is identified as an important warning sign.
• Treatment selection should be explained in relation to the patient's exact subtype and risk category. Patients should ask why a particular chemotherapy, targeted therapy, immunotherapy or other treatment protocol is being recommended and should request outcome information for patients with a similar diagnosis. Clear communication and willingness to answer direct questions are important parts of the vetting process.
• Hospital infrastructure is particularly important in blood cancer treatment because patients may require specialised diagnostic and supportive services. The guide recommends verifying NABH or JCI accreditation and confirming an in-house haematopathology laboratory capable of flow cytometry and genetic or molecular testing. Blood bank and transfusion support and appropriately controlled environments for immunocompromised patients should also be assessed.
• International-patient support is important for Bangladeshi patients because blood cancer treatment can require an extended period of care. The guide recommends checking for a dedicated international patient desk capable of assisting with visa invitation letters, payment and currency logistics, airport transfers and language support. The seven-step vetting journey shown on page 4 covers shortlisting, registration verification, case-volume confirmation, video consultation, written estimate, visa confirmation and travel booking.

Quick Facts

Treatment

Leukemia, lymphoma and blood cancer treatment

Primary Patients

Bangladeshi patients travelling to India

Main Treatment Options

Chemotherapy, targeted therapy, immunotherapy and bone marrow transplant when clinically appropriate

Key Specialist

Haematology-Oncology Specialist / Blood Cancer Team

Registration Check

National Medical Commission or relevant State Medical Council

Qualification Check

Relevant postgraduate qualification in haematology or medical oncology

Training Check

Specific fellowship training focused on blood cancers

Experience Check

Personal annual volume for the patient's exact diagnosis and molecular subtype

Diagnostic Subtyping

Bone marrow biopsy, flow cytometry and genetic or molecular testing should be considered before treatment is finalised

Protocol Selection

Treatment should be matched to the exact subtype and risk category

Transplant Assessment

Bone marrow transplant should be considered only when clinically relevant to the patient's subtype, risk and treatment response

Outcome Check

Ask for outcome information for patients with a similar diagnosis

Hospital Accreditation

NABH or JCI accreditation should be independently verified

Haematopathology Laboratory

In-house flow cytometry and genetic or molecular testing capability

Blood Bank

Reliable blood bank and transfusion support

Protected Care

Appropriate controlled environments for immunocompromised patients

International Support

Visa, payment, currency, airport-transfer and language assistance

Consultation

Video consultation recommended before travelling

Cost Documentation

Diagnostics, treatment and follow-up should be itemised separately

Team Confirmation

Specific doctor or treatment team should be confirmed in writing before travel

Follow-Up Planning

Extended treatment and follow-up requirements should be understood before travel

Patient Locations

Dhaka, Chittagong, Sylhet, Khulna and across Bangladesh

Red Flags

Pressure tactics, treatment before complete subtyping, vague pricing or unidentified treatment team

Decision Factor

High-volume blood cancer team with accurate diagnostic capability and subtype-specific treatment expertise

Author

Dr. Dheeraj Bojwani

Experience

24+ Years

In Brief

For Bangladeshi patients seeking leukemia, lymphoma or other blood cancer treatment in India, the guide recommends selecting the specific haematology-oncology team first and then evaluating the hospital around that team. Important checks include NMC or State Medical Council registration, relevant postgraduate and fellowship training, subtype-specific case volume and complete diagnostic subtyping through bone marrow biopsy, flow cytometry and genetic or molecular testing before treatment is finalised. Patients should also verify NABH or JCI accreditation, an in-house haematopathology laboratory, blood bank and transfusion support, protected care environments, international-patient services, transparent costing and written confirmation of the treating team.

Why India Is a Leading Destination for Leukemia, Lymphoma and Blood Cancer Treatment

India has built one of the world's largest and most experienced haematology-oncology ecosystems, driven by high domestic demand and decades of international patient volume from across South Asia, the Middle East and Africa. This scale matters in a very practical way: many Indian haematology-oncology teams manage a high volume of patients across the full range of blood cancers a year, and this experience, combined with genuine diagnostic accuracy, is one of the factors most consistently linked to selecting the right treatment protocol from the start. Combined with modern haematopathology laboratories, genuine access to targeted therapies and immunotherapy, NABH and JCI-accredited hospitals, and an established medical-visa pathway built specifically for Bangladeshi patients, India offers a genuinely credible option — provided you know how to identify the right team and hospital for your specific diagnosis.

How to Select an Experienced Haematology-Oncology Team in India from Bangladesh?

The single most important decision in your treatment is not the hospital's marketing or its lobby — it is the individual haematology-oncology specialist managing your case. Evaluate every candidate against these criteria before booking anything.

1. Verify Registration and Genuine Haematology-Oncology Qualification

Every practising doctor in India must be registered with the National Medical Commission (NMC) or a State Medical Council. Ask for the doctor's registration number and verify it directly through the NMC's own database rather than relying on a hospital website's claims. Look for a postgraduate qualification plus specific fellowship training in haematology or medical oncology with a genuine focus on blood cancers, since this is meaningfully different expertise from general oncology.

2. Ask About Subtype-Specific Case Volume, Not General Experience

"20 years of experience" tells you little on its own. Ask specifically how many patients with your exact diagnosis and molecular subtype the team manages personally each year, since treatment protocols and outcomes genuinely differ by specific blood cancer subtype. A team with genuinely high volume in your specific situation has a fundamentally different depth of expertise than one treating it occasionally.

3. Confirm Genuine, Accurate Diagnostic Subtyping Before Treatment Begins

Ask specifically what diagnostic testing — including bone marrow biopsy, flow cytometry and genetic or molecular testing — will be performed before your treatment protocol is finalised. For blood cancers, accurate subtyping genuinely changes which treatment gives you the best outcome, and a team that insists on this before starting treatment, rather than moving quickly to a generic protocol, is worth seeking out.

4. Ask About Treatment Protocol Selection and Outcome Data

Ask specifically why a particular treatment protocol is being recommended for your exact subtype and risk category, and ask the team to discuss their outcome data for patients with your specific diagnosis in plain terms. Vague reassurance without specifics is a signal to ask more questions, not fewer.

India Doctor Vetting Checklist: Blood Cancer

What Should Bangladeshi Patients Look for When Choosing a Blood Cancer Hospital in India?

The hospital matters almost as much as the team, because even excellent specialists working without a genuine haematopathology laboratory and appropriate supportive care for immunocompromised patients can still produce a disappointing outcome. Evaluate hospitals against these criteria specifically for blood cancer treatment, not their general reputation.

1. Confirm Genuine Accreditation

Look for NABH (National Accreditation Board for Hospitals) or JCI (Joint Commission International) accreditation, and verify it directly through the accreditation body's own online directory rather than trusting a logo on the hospital's website. Accreditation reflects independently audited standards for patient safety, infection control and clinical governance.

2. Look for a Genuine, Well-Equipped Haematopathology Laboratory

Confirm the hospital has a dedicated haematopathology laboratory capable of flow cytometry and genetic or molecular testing on-site, rather than sending samples elsewhere with resulting delays. Ask too about blood bank and transfusion support capability, and protected, appropriately controlled environments for patients whose immune systems are compromised during treatment.

3. Check International Patient Support Infrastructure

A hospital genuinely set up for Bangladeshi patients will have a dedicated international patient desk that can help with visa invitation letters, currency and payment logistics, airport transfers, and language support across the extended treatment period blood cancer care often requires. This infrastructure is a meaningful sign of real experience treating patients from abroad, not an afterthought.

Your Vetting and Booking Journey: A Step-by-Step Process

Use this structured process to move from an initial shortlist to a confirmed booking with genuine confidence in your choice.

Your Doctor & Hospital Vetting Journey

Questions to Ask Before You Book

Bring this list to every consultation, whether by video call or in person, and insist on specific, direct answers:

• "How many patients with my exact diagnosis do you personally manage each year?" — not the hospital's total, your specific team's number.
• "What diagnostic testing will be done before my treatment protocol is finalised?" — a specific answer covering biopsy, flow cytometry and genetic testing.
• "Why is this specific protocol right for my subtype and risk category?" — an honest, evidence-based answer.
• "What outcome data do you have for patients with my specific diagnosis?" — a confident team will answer this directly.
• "What exactly is included in this cost estimate?" — diagnostics, treatment and follow-up should all be itemised separately.

India Hospital Vetting Checklist: Blood Cancer

A Closing Words

India's combination of high-volume, haematology-fellowship-trained teams, genuine in-house diagnostic laboratories, internationally accredited hospitals and dramatically lower costs makes it a genuinely strong choice for leukemia, lymphoma and blood cancer treatment — but only when you choose the specific team and hospital carefully. The patients who report the smoothest experiences are consistently the ones who insisted on complete diagnostic subtyping, verified registration and case volume directly, and got everything in writing before booking travel. Treat this vetting process as seriously as the treatment itself, and India's genuine strengths in this field will work in your favour.

Sources

• 🌐 National Medical Commission of India — statutory body for verifying a doctor's registration and specialist qualifications. · nmc.org.in
• 🌐 National Accreditation Board for Hospitals & Healthcare Providers (NABH) — India's principal healthcare accreditation authority, under the Quality Council of India. · nabh.co
• 🌐 Joint Commission International (JCI) — international healthcare accreditation body with a public directory of accredited hospitals worldwide, including in India. · jointcommissioninternational.org
• 🌐 Determinants of Bangladeshi patients' decision-making process and satisfaction toward medical tourism in India. Peer-reviewed study, hosted via NIH/NCBI. · pmc.ncbi.nlm.nih.gov/articles/PMC10185743
• 🌐 Government of India — Medical Value Travel / e-Medical Visa Portal, Bureau of Immigration, Ministry of Home Affairs — official channel for hospital invitation letters and medical-visa provisions for Bangladeshi nationals. · indianfrro.gov.in/frro/medicalvaluetravel

Frequently Asked Questions by Bangladeshi Patients about Best Leukemia, Lymphoma and Blood Cancer Treatment Doctors and Hospitals in India

How can Bangladeshi patients choose the right blood cancer specialist in India?

Patients should verify the doctor's registration, relevant postgraduate qualification, blood-cancer-focused fellowship training and experience with their exact diagnosis and molecular subtype. A video consultation should also be completed before travelling.

How can Bangladeshi patients verify an Indian blood cancer doctor's registration?

They should request the doctor's registration number and independently verify it through the National Medical Commission or relevant State Medical Council rather than relying solely on hospital information.

Why does exact molecular subtyping matter so much for leukemia and lymphoma?

Blood cancers contain different subtypes with distinct genetic and molecular characteristics. The guide explains that this information can directly influence which treatment protocol is appropriate for the patient.

What diagnostic tests should Bangladeshi patients ask about before treatment?

Patients should ask whether bone marrow biopsy, flow cytometry and genetic or molecular testing will be performed before the treatment protocol is finalised. The exact tests depend on the patient's suspected diagnosis.

How much blood cancer experience should Bangladeshi patients ask about?

Patients should ask how many people with their exact diagnosis and molecular subtype the team personally manages each year. General oncology volume does not necessarily demonstrate specific blood cancer expertise.

Will every Bangladeshi blood cancer patient need a bone marrow transplant?

No. The guide states that many blood cancers can be treated with chemotherapy, targeted therapy or immunotherapy, while transplant is reserved for specific situations based on subtype, risk category and response to initial treatment.

What should Bangladeshi patients check about a blood cancer hospital in India?

They should verify NABH or JCI accreditation and confirm an in-house haematopathology laboratory, flow cytometry and genetic or molecular testing, blood bank and transfusion support and appropriately controlled environments for immunocompromised patients.

Can Bangladeshi patients have a video consultation with an Indian blood cancer specialist?

Yes. The guide recommends a video consultation so the specialist can review the patient's medical history and available reports and explain the proposed diagnostic and treatment approach before travel.

What should be included in a blood cancer treatment cost estimate?

The written estimate should separately identify diagnostics, treatment and follow-up. Patients should clarify what is included before travelling, particularly because blood cancer treatment may extend over a longer period.

What should Bangladeshi patients confirm before travelling to India for blood cancer treatment?

They should verify the specialist's credentials and subtype-specific experience, confirm complete diagnostic subtyping, understand why the proposed protocol fits their diagnosis and risk category, verify hospital laboratory and supportive-care facilities, obtain an itemised estimate and confirm the named treatment team in writing before booking travel.

Page Summary

This six-page guide helps Bangladeshi patients evaluate doctors and hospitals in India for leukemia, lymphoma and other blood cancers. It explains why blood cancer treatment requires more than a general oncology assessment, with accurate diagnostic subtyping through bone marrow biopsy, flow cytometry and genetic or molecular testing playing an important role in treatment selection. Patients are advised to verify NMC or State Medical Council registration, relevant postgraduate qualifications, blood-cancer-focused fellowship training and experience with their exact diagnosis and molecular subtype. The guide also encourages patients to ask why a particular treatment protocol is appropriate for their subtype and risk category.

Citation Block

Field	Information
Article / Topic	Best Leukemia, Lymphoma and Blood Cancer Treatment Doctors and Hospitals in India
Country / Patients	India / Bangladeshi Patients
Main Treatment	Leukemia, lymphoma and blood cancer treatment
Key Specialist	Haematology-Oncology Specialist / Blood Cancer Team
Main Treatment Options	Chemotherapy, targeted therapy, immunotherapy and transplant when appropriate
Doctor Registration	Verify NMC or State Medical Council registration directly
Specialist Qualification	Relevant postgraduate qualification
Blood Cancer Training	Specific fellowship training in haematology or medical oncology
Subtype-Specific Volume	Confirm the team's personal experience with the exact diagnosis and molecular subtype
Diagnostic Subtyping	Bone marrow biopsy, flow cytometry and genetic or molecular testing before treatment is finalised
Protocol Selection	Confirm why the proposed treatment is appropriate for the subtype and risk category
Outcome Data	Ask about outcomes for patients with a similar diagnosis
Hospital Accreditation	NABH or JCI should be independently verified
Haematopathology Laboratory	In-house flow cytometry and genetic or molecular testing
Blood Bank & Supportive Care	Confirm transfusion support and protected care environments
International Patient Desk	Visa, payment, currency, airport-transfer and language support
Video Consultation	Recommended before committing to travel
Written Estimate	Diagnostics, treatment and follow-up should be itemised separately
Named Team	Specific doctor or treatment team should be confirmed in writing
Key Patient Questions	Subtype-specific volume, diagnostic testing, protocol selection, outcomes and cost
Red Flags	Pressure tactics, treatment before complete subtyping, vague pricing or unidentified team
Key Selection Criterion	High-volume blood cancer team with accurate diagnostics and subtype-specific treatment expertise
Important Warning	Do not choose solely on hospital reputation or price; independently verify specialist credentials, diagnostic capabilities, subtype-specific experience, hospital infrastructure and the named treatment team